Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eukarys is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter represents the full extent of the company's current patent prosecution. The workload is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a highly specialized technical focus for the company's current patenting efforts. This streamlined structure suggests that the company is focusing its resources on a specific innovation within the biotechnology or pharmaceutical fields.
The busiest examiner for the portfolio is PAULUS, ERIN VIRGINIA, who is handling 1 busiest examiner pending office action. Given that this 1 pending office action is the only one active, the examiner's specific interpretation of the claims will be the primary factor in the portfolio's progress. The presence of only 1 distinct examiner and 1 distinct art unit simplifies the prosecution landscape, as there are no competing examiner perspectives to manage. Practitioners should focus on the specific technical standards of the Biotechnology & Pharmaceuticals area to effectively address the concerns raised in this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017967 | ARTIFICIAL EUKARYOTIC EXPRESSION SYSTEM WITH ENHANCED PERFORMANCES | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017967 | ARTIFICIAL EUKARYOTIC EXPRESSION SYSTEM WITH ENHANCED PERFORMANCES | PAULUS, ERIN VIRGINIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017967 | ARTIFICIAL EUKARYOTIC EXPRESSION SYSTEM WITH ENHANCED PERFORMANCES | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | — | Pending | Jan 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEukarys has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erin Virginia Paulus has the most, with 1 of Eukarys's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
